Five exciting new patent documents (published February 2-16, 2012) are on the board today: gemifloxacin for neuroprotection; amlexalox for nonsense-mutation-mediated genetic diseases; alpha2a receptor blockers for liver cirrhosis; the established antihelminthic, moxidectin and the pain drug candidate radiprodil for neuropsychiatry.H.M. Pharma Consultancy specializes in drug repurposing opportuniti...

Today we highlight four PCT documents published between January 12 and February 2, 2012: cancer drug candidates for neglected tropical diseases; ifetroban, a THX2 receptor blocker, for hepatic encephalopathy; the oral antidiabetic, glibeclamide for peripheral and CNS ischemia and injury; and losartan for psoriasis.Forward The Patentome!mTOR/PI3K Inhibitors for Trypanosomatid DiseasesNVP-BEZ-235The...

Patent databases are proliferating. There is not a single IP document published by the major offices (and an increasing number of smaller ones) that you could not download – free of charge because patent law demands distribution of information in exchange for granting exclusivity. In addition to all the usual Boolean searches for inventors, assignees and IPC categorization codes, the public databa...

Ah, what a month January has been! The power of networking and collaboration is making itself felt. Our business development path until midyear has been mapped, as far as such planning can go. No guarantees of course - there are no such things if you are working in the truly independent line. To paraphrase Clausewitz' pun on battles, no business plan survives contact with reality as long as you ar...

Here is our first post focusing on international patent applications that concern themselves with some new applications for known or discontinued drugs. In this pilot issue we highlight documents published between December 29, 2011 and January 12, 2012.H.M. Pharma Consultancy is a leader in knowledge extraction from drug repurposing patent documents, and gives strategic advice to developers lookin...

In March 2012, the Future Science Group will launch a paper and online subscription journal, the Pharmaceutical Patent Analyst (PPA; ISSN 2046-8954). It will highlight and review patents of relevance to pharmaceutical science across all therapeutic areas, from small molecules to biologics. We are happy that H.M. Pharma Consultancy has been given the opportunity to establish a presence on PPA's int...

Right before the New Year rockets are launched, we once again present and discuss some interesting life science patent disclosures. See you again in 2012! PLEASE CITE AS : Mucke HAM. Patent Highlights for December 2011. Published online on the H.M. Pharma Consultancy Blog (URL:http://hmpharmacon.blogspot.com/2011/12/patent-highlights-for-december-2011.html) on December 30, 2011. Contact us at of...

During today's latest summit to save the Euro monetary union (and for once, it was a decisive summit!) , the United Kingdom has taken clear steps towards detaching itself even more from European collaboration and integration. That might serve to bolster the financial sector in London's City, but if Mr. Cameron's "bulldog fight" will really serve the country's overall best interests in the longer ...

Greetings to our followers! Here are eight international patent applications from the life sciences published in October 2011, plus two that have the October 27 date but came online only in November after our last issue of these Patent Highlights was published. This review has new drugs for malaria, tuberculosis and viral infections; personalized therapy for Fragile X syndrome; a progranulin antib...

Vaccines - Preceding Drugs Then, Revolutionizing Therapy Now Our recent Protein Engineering Report (see here) has been very well received, and now Cambridge Healthtech Institute has published another report from our "Beyond Small Molecule" series. This time the subject is vaccines, and it looks like this piece is really hitting a nerve; the interest has been tremendous. You can access information...